Evidence map›Paper›PMID 28947731›Full record

ArticleAnnals of transplantation2017

Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.

Fumiaki Kitazawa, Shin-Ichi Fuchida, Yoko Kado, Kumi Ueda, Takatoshi Kokufu, Akira Okano, Mayumi Hatsuse, Satoshi Murakami, Yuko Nakayama, Kohji Takara and 1 more

Open access · greenAbstract read
In one paragraph

Article in Annals of transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 15 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fumiaki KitazawaDepartment of Pharmacy, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Shin-Ichi FuchidaDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Yoko KadoDepartment of Pharmacy, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Kumi UedaDepartment of Pharmacy, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Takatoshi KokufuDepartment of Pharmacy, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Akira OkanoDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Mayumi HatsuseDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Satoshi MurakamiDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Yuko NakayamaDepartment of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hyogo, Japan.
Kohji TakaraDepartment of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hyogo, Japan.
Chihiro ShimazakiDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto City, Kyoto, Japan.
Kyoto Medical Center · JPHimeji Dokkyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Tacrolimus and fentanyl are well-known cytochrome P450 (CYP) 3A4 substrates with a narrow therapeutic range. However, the pharmacokinetic interaction between tacrolimus and fentanyl is unclear. The aim of this study was to determine whether drug interaction exists between tacrolimus and fentanyl. MATERIAL AND METHODS A retrospective study was performed in 6 patients who had received allogeneic hematopoietic stem cell transplantation between April 2010 and March 2015. The patients received continuous intravenous infusion of fentanyl with concomitant use of tacrolimus, and the blood concentrations of tacrolimus were evaluated using fluorescence polarization immunoassay. RESULTS The clearance (CL) of tacrolimus decreased significantly from 1.28 to 0.68 mL/min/kg with concomitant use of fentanyl. The CL changed with time and dose of fentanyl administration. In addition, the CL of tacrolimus was reverted by stopping fentanyl infusion. Horn's drug interaction probability scale indicated a probable category or possible category, suggesting a drug interaction between tacrolimus and fentanyl. No patient showed a difference in hepatic or renal function before and after fentanyl administration. No additional administration of other CYP3A4 inhibitors was observed, suggesting that the drug interaction was mediated by CYP3A4. CONCLUSIONS The influence of fentanyl on the pharmacokinetics of tacrolimus was demonstrated to be of clinical importance. It is proposed that the dose of tacrolimus be reduced by 40% when used in combination with fentanyl.

Indexed as

AdultAgedAnesthetics, IntravenousDrug InteractionsFemaleFentanylHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesTacrolimusAnesthetics, IntravenousFentanylImmunosuppressive AgentsTacrolimus

Identifiers

PMID28947731
PMCPMC12574104
OpenAlexW2757261108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.